From chimps to chips: Organs on a chip for testing of pharmaceutical compounds

The pharmaceutical industry invests vast sums of money to develop new drug therapies for a variety of conditions. To take a drug from lab to clinic, both in vitro and in vivo models are deployed to prove efficacy, safety and kinetics. Organ on Chip technologies present an alternative to classic in vitro models and attempt to rival the capabilities of more established in vivo technologies. This presentation discusses the benefits, limitations and future of the technology. CN Bio develops microfluidic organ-on-a-chip platforms which permit a more physiologically relevant study of biology, pathology and drug responses in vitro, prior to human clinical trials.